{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T07:19:44Z","timestamp":1724743184358},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T00:00:00Z","timestamp":1710115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T00:00:00Z","timestamp":1710115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Globally, 80\u00a0million people are suffering from chronic Hepatitis C virus (HCV) infection. Sofosbuvir ribavirin-based anti-HCV therapy is associated with anemia and other adverse effects. Polymorphisms of Inosine triphosphatase (<jats:italic>ITPA<\/jats:italic>) gene may cause functional impairment in the Inosine triphosphate pyrophosphatase enzyme, resulting in enhanced sustained viral response (SVR) and protection from ribavirin-associated anemia in patients on therapy. The study objective was to investigate the effect of Inosine triphosphatase gene polymorphism on SVR achievement, hemoglobin decline and ribavirin dose reduction in patients on therapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This prospective cohort study was of 170 hepatitis C infected patients received 6-month sofosbuvir ribavirin therapy. Patient viral load, reduction in ribavirin amount, liver function test, and complete blood count were noted monthly. Inosine triphosphatase variants rs1127354 and rs7270101 were assessed through the restriction fragment length polymorphism and confirmed using Sanger sequencing. The impact of polymorphism on cumulative reduction of ribavirin, and anti-HCV therapy outcome were studied.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 74.3% of patients had <jats:italic>ITPA<\/jats:italic> rs1127354 CC genotype, 25.7% were CA and AA 0%. The frequency of <jats:italic>ITPA<\/jats:italic> genotype rs7270101-AA was 95%, AC 5%, and CC was 0%. <jats:italic>ITPA<\/jats:italic> rs1127354-CA had a notably positive impact on SVR achievement with a zero-relapse rate. <jats:italic>ITPA<\/jats:italic> rs1127354-CA genotype was significantly (<jats:italic>P<\/jats:italic> \u02c20.05) protective against \u2265\u20092\u00a0g\/dl Hb reduction from baseline to 1st, 2nd and 6th months of therapy. During treatment, Hb reduction\u2009\u2265\u200910\u00a0g\/dl was frequently observed in rs1127354-CC genotype and rs7270101-AA genotype patients. Ribavirin dose reduction was significantly (<jats:italic>P<\/jats:italic> \u02c20.05) high in rs1127354-CC genotype as compared to genotype CA whereas no significant difference was observed in ribavirin dose reduction in rs7270101 AA and non-AA genotype. Patient baseline characteristics such as age, body mass index, rs1127354-CC genotype, and baseline Hb were significantly associated with significant Hb reduction.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Pretreatment evaluation of <jats:italic>ITPA<\/jats:italic> polymorphism can be a diagnostic tool to find out patients at risk of anemia and improve treatment adherence. ITPA genotype rs1127354-CA contributes to improved compliance with ribavirin dose and protects against hemoglobin decline in HCV patients while taking ribavirin-based therapy. However, <jats:italic>ITPA<\/jats:italic> rs1127354, rs7270101 polymorphism have no significant impact on SVR achievement.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-024-09188-1","type":"journal-article","created":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T09:01:32Z","timestamp":1710147692000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of ITPA gene polymorphism for predicting anemia and treatment outcome in HCV infected patients taking Sofosbuvir Ribavirin therapy"],"prefix":"10.1186","volume":"24","author":[{"given":"Sameen","family":"Amjed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hafiz Ghulam Murtaza","family":"Saleem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sajjad","family":"Ullah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahzad","family":"Latif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Shabana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junaid","family":"Jafar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad Bilal","family":"Waqar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,11]]},"reference":[{"issue":"4","key":"9188_CR1","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1089\/vim.2016.0164","volume":"30","author":"MS Afzal","year":"2017","unstructured":"Afzal MS. Hepatitis C virus and interferon-free antiviral therapeutics revolution: implications for Pakistan. Viral Immunol. 2017;30(4):252\u20137.","journal-title":"Viral Immunol"},{"key":"9188_CR2","doi-asserted-by":"crossref","unstructured":"Jafar J, Junaid K, Saleem K, Amjed S, Arshad F, Amjed T, Raja N, Gillani A. Hypovitaminosis D in Hepatitis C patients and its relation with demographic and laboratory data. JPMA 2019.","DOI":"10.5455\/JPMA.301067"},{"issue":"1","key":"9188_CR3","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jhep.2013.07.043","volume":"60","author":"AJ van der Meer","year":"2014","unstructured":"van der Meer AJ, Wedemeyer H, Feld JJ, Hansen BE, Manns MP, Zeuzem S, Janssen HL. Is there sufficient evidence to recommend antiviral therapy in hepatitis C? J Hepatol. 2014;60(1):191\u20136.","journal-title":"J Hepatol"},{"issue":"6","key":"9188_CR4","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1111\/jcpt.13232","volume":"45","author":"Z Ma","year":"2020","unstructured":"Ma Z, Sun Y, Du P, Li X. Association between inosine triphosphatase rs1127354 polymorphisms and Ribavirin-induced anaemia and outcome in hepatitis C virus\u2010infected patients: a meta\u2010analysis. J Clin Pharm Ther. 2020;45(6):1218\u201327.","journal-title":"J Clin Pharm Ther"},{"key":"9188_CR5","doi-asserted-by":"crossref","unstructured":"Kozuka R, Hai H, Teranishi Y, Motoyama H, Kawamura E, Hagihara A, Uchida-Kobayashi S, Morikawa H, Enomoto M, Murakami Y. ITPA polymorphism correlates with the reductions in hemoglobin concentration and Ribavirin dose during sofosbuvir and Ribavirin therapy. J Gastroenterol Hepatol 2017.","DOI":"10.1111\/jgh.13743"},{"issue":"1","key":"9188_CR6","first-page":"1","volume":"3","author":"MP Manns","year":"2017","unstructured":"Manns MP, Buti M, Gane E, Pawlotsky J-M, Razavi H, Terrault N, Younossi Z. Hepatitis C virus infection. Nat Reviews Disease Primers. 2017;3(1):1\u201319.","journal-title":"Nat Reviews Disease Primers"},{"issue":"5","key":"9188_CR7","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1093\/cid\/civ396","volume":"61","author":"B Simmons","year":"2015","unstructured":"Simmons B, Saleem J, Heath K, Cooke GS, Hill A. Long-term treatment outcomes of patients infected with hepatitis C virus: a systematic review and meta-analysis of the survival benefit of achieving a sustained virological response. Clin Infect Dis. 2015;61(5):730\u201340.","journal-title":"Clin Infect Dis"},{"key":"9188_CR8","doi-asserted-by":"crossref","unstructured":"Schaefer EA, Chung RT. The impact of human gene polymorphisms on HCV infection and disease outcome. Seminars in liver disease: 2011. \u00a9 Thieme Medical; 2011. pp. 375\u201386.","DOI":"10.1055\/s-0031-1297926"},{"issue":"3","key":"9188_CR9","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1089\/vim.2016.0136","volume":"30","author":"KC Bagley","year":"2017","unstructured":"Bagley KC, Schwartz JA, Andersen H, Eldridge JH, Xu R, Ota-Setlik A, Geltz JJ, Halford WP, Fouts TR. An interleukin 12 adjuvanted herpes simplex virus 2 DNA vaccine is more protective than a glycoprotein D subunit vaccine in a high-dose murine challenge model. Viral Immunol. 2017;30(3):178\u201395.","journal-title":"Viral Immunol"},{"issue":"10","key":"9188_CR10","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.2217\/pgs.15.65","volume":"16","author":"K Rembeck","year":"2015","unstructured":"Rembeck K, Lagging M. Impact of IL28B, ITPA and PNPLA3 genetic variants on therapeutic outcome and progression of hepatitis C virus infection. Pharmacogenomics. 2015;16(10):1179\u201388.","journal-title":"Pharmacogenomics"},{"issue":"7287","key":"9188_CR11","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/nature08825","volume":"464","author":"J Fellay","year":"2010","unstructured":"Fellay J, Thompson AJ, Ge D, Gumbs CE, Urban TJ, Shianna KV, Little LD, Qiu P, Bertelsen AH, Watson M. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature. 2010;464(7287):405\u20138.","journal-title":"Nature"},{"issue":"4","key":"9188_CR12","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1053\/j.gastro.2010.06.071","volume":"139","author":"H Ochi","year":"2010","unstructured":"Ochi H, Maekawa T, Abe H, Hayashida Y, Nakano R, Kubo M, Tsunoda T, Hayes CN, Kumada H, Nakamura Y. ITPA polymorphism affects Ribavirin-induced anemia and outcomes of therapy\u2014a genome-wide study of Japanese HCV virus patients. Gastroenterology. 2010;139(4):1190\u20137. e1193.","journal-title":"Gastroenterology"},{"issue":"2","key":"9188_CR13","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1053\/j.gastro.2018.09.052","volume":"156","author":"TR O\u2019Brien","year":"2019","unstructured":"O\u2019Brien TR, Yang H-I, Groover S, Jeng W-J. Genetic factors that affect spontaneous clearance of hepatitis C or B virus, response to treatment, and disease progression. Gastroenterology. 2019;156(2):400\u201317.","journal-title":"Gastroenterology"},{"issue":"10","key":"9188_CR14","doi-asserted-by":"publisher","first-page":"e0139317","DOI":"10.1371\/journal.pone.0139317","volume":"10","author":"R Maan","year":"2015","unstructured":"Maan R, van der Meer AJ, Brouwer WP, Plompen EP, Sonneveld MJ, Roomer R, van der Eijk AA, Groothuismink ZM, Hansen BE, Veldt BJ. ITPA polymorphisms are associated with hematological side effects during antiviral therapy for chronic HCV infection. PLoS ONE. 2015;10(10):e0139317.","journal-title":"PLoS ONE"},{"issue":"8","key":"9188_CR15","doi-asserted-by":"publisher","first-page":"925","DOI":"10.2217\/pgs.16.22","volume":"17","author":"A D\u2019Avolio","year":"2016","unstructured":"D\u2019Avolio A, Cusato J, De Nicol\u00f2 A, Allegra S, Di Perri G. Pharmacogenetics of Ribavirin-induced anemia in HCV patients. Pharmacogenomics. 2016;17(8):925\u201341.","journal-title":"Pharmacogenomics"},{"issue":"12","key":"9188_CR16","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1111\/jvh.12113","volume":"20","author":"P Clark","year":"2013","unstructured":"Clark P, Aghemo A, Degasperi E, Galmozzi E, Urban T, Vock D, Patel K, Thompson A, Rumi M, D\u2019Ambrosio R. Inosine triphosphatase deficiency helps predict anaemia, anaemia management and response in chronic hepatitis C therapy. J Viral Hepatitis. 2013;20(12):858\u201366.","journal-title":"J Viral Hepatitis"},{"issue":"10","key":"9188_CR17","doi-asserted-by":"publisher","first-page":"E84","DOI":"10.1111\/hepr.12224","volume":"44","author":"H Ishida","year":"2014","unstructured":"Ishida H, Sakane S, Toyama T, Fukutomi K, Kimura K, Sugimoto A, Hibino K, Tamura T, Iwasaki T, Iwasaki R. Administration of low-dose epoetin\u2010alpha facilitates adherence to Ribavirin in triple therapy with pegylated interferon\u2010alpha\u20102b and telaprevir. Hepatol Res. 2014;44(10):E84\u201391.","journal-title":"Hepatol Res"},{"issue":"4","key":"9188_CR18","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.jhep.2013.05.017","volume":"59","author":"E Ogawa","year":"2013","unstructured":"Ogawa E, Furusyo N, Nakamuta M, Kajiwara E, Nomura H, Dohmen K, Takahashi K, Satoh T, Azuma K, Kawano A. Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy. J Hepatol. 2013;59(4):667\u201374.","journal-title":"J Hepatol"},{"issue":"10","key":"9188_CR19","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1002\/jmv.24528","volume":"88","author":"Y Tahata","year":"2016","unstructured":"Tahata Y, Hiramatsu N, Oze T, Urabe A, Morishita N, Yamada R, Yakushijin T, Hosui A, Oshita M, Kaneko A. Impact of Ribavirin dosage in chronic hepatitis C patients treated with simeprevir, pegylated interferon plus Ribavirin combination therapy. J Med Virol. 2016;88(10):1776\u201384.","journal-title":"J Med Virol"},{"key":"9188_CR20","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jcv.2015.05.010","volume":"68","author":"J Ampuero","year":"2015","unstructured":"Ampuero J, Del Campo JA, Rojas L, Calleja JL, Cabezas J, Lens S, Crespo J, Forns X, Andrade RJ, Fern\u00e1ndez I. Role of ITPA and SLC28A2 genes in the prediction of anaemia associated with protease inhibitor plus Ribavirin and peginterferon in hepatitis C treatment. J Clin Virol. 2015;68:56\u201360.","journal-title":"J Clin Virol"},{"issue":"7","key":"9188_CR21","doi-asserted-by":"publisher","first-page":"e22440","DOI":"10.1002\/jcla.22440","volume":"32","author":"SE Alavian","year":"2018","unstructured":"Alavian SE, Sharafi H, Shirmast P, Alavian SM, Behnava B, Pouryasin M, Keshvari M, Pouryasin A. A facile PCR-RFLP method for genotyping of ITPA rs1127354 and rs7270101 polymorphisms. J Clin Lab Anal. 2018;32(7):e22440.","journal-title":"J Clin Lab Anal"},{"key":"9188_CR22","unstructured":"Iranpur V, Esmailizadeh A, Horriat R. Rapid Extraction of High Quality DNA from Whole Blood Stored at 4\u2218 C for Long Period. Protocol online Retrieved from: http:\/\/www protocol-online org\/prot\/Protocols\/Rapid-Extraction-of-High-Quality-DNA-from-Whole-Blood-Stored-at-4-C-for-Long-Period-4175 2010."},{"issue":"3","key":"9188_CR23","first-page":"381","volume":"10","author":"S Amjed","year":"2023","unstructured":"Amjed S, Saleem HGM, Ullah S, Latif S, Irfan S, Jafar J, Waqar AB. Protective role of ITPA rs1127354-CA polymorphism against anemia in HCV patients using Sofosbuvir Ribavirin therapy: age and gender match case-control study. Advancements Life Sci. 2023;10(3):381\u20139.","journal-title":"Advancements Life Sci"},{"issue":"12","key":"9188_CR24","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1111\/hepr.12681","volume":"46","author":"K Morio","year":"2016","unstructured":"Morio K, Imamura M, Kawakami Y, Morio R, Hatooka M, Kan H, Fujino H, Fukuhara T, Kobayashi T, Masaki K. Effects of ITPA polymorphism on decrease of hemoglobin during simeprevir, peg-interferon, and Ribavirin combination treatment for chronic hepatitis C. Hepatol Res. 2016;46(12):1256\u201363.","journal-title":"Hepatol Res"},{"issue":"6","key":"9188_CR25","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1007\/s00535-016-1279-9","volume":"52","author":"K Morio","year":"2017","unstructured":"Morio K, Imamura M, Kawakami Y, Nakahara T, Nagaoki Y, Kawaoka T, Tsuge M, Hiramatsu A, Aikata H, Hayes CN. ITPA polymorphism effects on decrease of hemoglobin during sofosbuvir and Ribavirin combination treatment for chronic hepatitis C. J Gastroenterol. 2017;52(6):746\u201353.","journal-title":"J Gastroenterol"},{"issue":"2","key":"9188_CR26","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1002\/hep.24068","volume":"53","author":"AJ Thompson","year":"2011","unstructured":"Thompson AJ, Santoro R, Piazzolla V, Clark PJ, Naggie S, Tillmann HL, Patel K, Muir AJ, Shianna KV, Mottola L. Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2\/3 but do not decrease dose reductions of RBV or increase SVR. Hepatology. 2011;53(2):389\u201395.","journal-title":"Hepatology"},{"issue":"8","key":"9188_CR27","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.3346\/jkms.2013.28.8.1213","volume":"28","author":"JS Kim","year":"2013","unstructured":"Kim JS, Ahn S-M, Jung YK, Kwon OS, Kim YS, Choi DJ, Kim JH. The impact of inosine triphosphatase variants on hemoglobin level and sustained virologic response of chronic hepatitis C in Korean. J Korean Med Sci. 2013;28(8):1213\u20139.","journal-title":"J Korean Med Sci"},{"key":"9188_CR28","unstructured":"Rahman IU, Siraj S, Aqeel M, Khan MTM, Hussain A. Association of Inosine Triphosphatase Polymorphysims rs7270101 and rs1127354 with the occurrence of Anemia in Hepatitis C patients receiving Pegylated Interferon and Ribavirin. Int J Pathol 2019:208\u201312."},{"issue":"4","key":"9188_CR29","first-page":"295","volume":"27","author":"I Ali","year":"2019","unstructured":"Ali I, Gul A, Sahar AN, Niaz S, Rahman S, Khan IA, Jamil J. RESPONSE RATE OF SOFOSBUVIR BASED ANTIVIRAL THERAPY AMONG PATIENTS INFECTED WITH HEPATITIS C VIRUS GENOTYPE 3A. J Med Sci. 2019;27(4):295\u2013301.","journal-title":"J Med Sci"},{"key":"9188_CR30","doi-asserted-by":"crossref","unstructured":"Haider SA, Ahmad B, Ali S, Haider A, Bashir S, Mahmood N. Sofosbuvir and Ribavirin Combination Therapy response in various Hepatitis C virus genotypes in Peshawar, Khyber Pakhtunkhwa. Jundishapur J Microbiol 2020, 13(6).","DOI":"10.5812\/jjm.99625"},{"issue":"8","key":"9188_CR31","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1111\/hepr.13354","volume":"49","author":"A Urabe","year":"2019","unstructured":"Urabe A, Sakamori R, Tahata Y, Yamada R, Imai Y, Hagiwara H, Tamura S, Fukui H, Yamada Y, Kaneko A. Predictive factors of anemia during sofosbuvir and Ribavirin therapy for genotype 2 chronic hepatitis C patients. Hepatol Res. 2019;49(8):853\u20139.","journal-title":"Hepatol Res"},{"issue":"10","key":"9188_CR32","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1002\/jmv.24844","volume":"89","author":"M El Raziky","year":"2017","unstructured":"El Raziky M, Zayed NA, Abdel Baki A, Mansour SA, Shahin RM. ITPA gene polymorphism (94C\u2009>\u2009A) effects on Ribavirin-induced anemia during therapy in Egyptian patients with chronic hepatitis C. J Med Virol. 2017;89(10):1823\u20139.","journal-title":"J Med Virol"},{"issue":"3","key":"9188_CR33","doi-asserted-by":"publisher","first-page":"170","DOI":"10.32413\/pjph.v8i3.190","volume":"8","author":"ZA Shaikh","year":"2018","unstructured":"Shaikh ZA, Shamim J, Nankani K, RIBAVIRIN INDUCED ANEMIA: A CROSS SECTIONAL STUDY AMONG PATIENTS WITH HEPATITIS C, VISITING OUT PATIENT DEPARTMENT OF A MAJOR PUBLIC SECTOR TERTIARY CARE HOSPITAL. KARACHI, PAKISTAN. Pakistan J Public Health. 2018;8(3):170\u20133.","journal-title":"Pakistan J Public Health"},{"issue":"1","key":"9188_CR34","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s12664-016-0618-3","volume":"35","author":"N Nemr","year":"2016","unstructured":"Nemr N, Kishk R, Mandour M. Role of ITPA gene polymorphism in Ribavirin-induced anemia and thrombocytopenia in Egyptian patients with chronic hepatitis C. Indian J Gastroenterol. 2016;35(1):7\u201313.","journal-title":"Indian J Gastroenterol"},{"issue":"6","key":"9188_CR35","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1002\/jmv.22069","volume":"83","author":"T Azakami","year":"2011","unstructured":"Azakami T, Hayes CN, Sezaki H, Kobayashi M, Akuta N, Suzuki F, Kumada H, Abe H, Miki D, Tsuge M. Common genetic polymorphism of ITPA gene affects Ribavirin-induced anemia and effect of peg\u2010interferon plus Ribavirin therapy. J Med Virol. 2011;83(6):1048\u201357.","journal-title":"J Med Virol"},{"issue":"2","key":"9188_CR36","doi-asserted-by":"publisher","first-page":"214","DOI":"10.5009\/gnl14095","volume":"9","author":"J-J Hwang","year":"2015","unstructured":"Hwang J-J, Lo C-C, Lin C-H, Cheng H-S, Hung I-W, Tsai W-J, Hung C-H. Association between IPTA gene polymorphisms and hematological abnormalities in hepatitis C virus-infected patients receiving combination therapy. Gut Liver. 2015;9(2):214.","journal-title":"Gut Liver"},{"issue":"4","key":"9188_CR37","doi-asserted-by":"publisher","first-page":"e00811","DOI":"10.1002\/prp2.811","volume":"9","author":"C Smirne","year":"2021","unstructured":"Smirne C, D\u2019Avolio A, Bellan M, Gualerzi A, Crobu MG, Pirisi M. Sofosbuvir-based therapies in genotype 2 hepatitis C virus cirrhosis: a real\u2010life experience with focus on Ribavirin dose. Pharmacol Res Perspect. 2021;9(4):e00811.","journal-title":"Pharmacol Res Perspect"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-09188-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-024-09188-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-09188-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T09:01:52Z","timestamp":1710147712000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-024-09188-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,11]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["9188"],"URL":"https:\/\/doi.org\/10.1186\/s12879-024-09188-1","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,11]]},"assertion":[{"value":"5 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted after taking approval from Institutional review board of FRAHS, UIMLT department The University of Lahore, Pakistan.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"301"}}